international first quarter of 2026) through 2028. Deferred revenues associated with contracts for other products were not significant as of December 31, 2024 or December 31, 2023.
Selected Quarterly Financial Data (Unaudited)
Pfizer Inc. and Subsidiary Companies
(a)
Business development activities impacted our results of operations in 2024
.
See
Note 1A
.
Due to the commercial market transition as well as the seasonality of demand for COVID-19 vaccinations, the majority of our global revenues for Comirnaty were recorded in the fourth quarter of 2024.
(b)
The fourth quarter historically reflects higher costs in
Cost of sales, Selling, informational and administrative expenses
and
Research and development expenses. Cost of sales
for all quarters reflects higher costs from our Seagen acquisition, inclusive of the amortization of the fair value step-up of inventory. See
Note 2A
.
Certain asset impairments totaled $2.9 billion in the fourth quarter. See
Note
4
.
(c)
The second quarter of 2024 primarily includes employee termination costs associated with our Manufacturing Optimization Program. The fourth quarter of 2024 primarily includes charges for asset impairments, exit costs and employee termination costs associated with our Realigning our Cost Base Program. See
Note 3
.
(d)
All periods reflect changes primarily the result of jurisdictional mix of earnings. The third quarter reflects tax benefits related to the closing of the IRS audits covering multiple tax years and the fourth quarter reflects tax benefits related to the Transition Tax liability under the TCJA. See
Note 5A
.
Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS amounts may not agree to the total for the year.
Selected Quarterly Financial Data (Unaudited)
Pfizer Inc. and Subsidiary Companies
(a)
On December 14, 2023, we completed the acquisition of Seagen. In addition, other business development activities impacted our results of operations in 2023
.
See
Note 1A
.
Due to the commercial market transition as well as the seasonality of demand for COVID-19 vaccinations, the majority of our global revenues for Comirnaty were recorded in the second half of 2023.
(b)
The fourth quarter historically reflects higher costs in
Cost of sales,
Selling, informational and administrative expenses
and
Research and development expenses.
The third quarter of 2023 reflects a non-cash charge of $5.6 billion to
Cost of sales
for inventory write-offs and related charges ($4.7 billion for Paxlovid and $0.9 billion for Comirnaty). Certain asset impairments totaled $2.8 billion in the fourth quarter of 2023 recorded in
Other (income)/deductions—net
. See
Note
4
.
(c)
The fourth quarter of 2023 primarily includes (i) charges of $1.5 billion for employee termination costs associated with our Realigning our Cost Base Program and (ii) integration and other costs of $587 million, mostly related to our acquisition of Seagen. See
Note 3
.